A detailed history of Tower Research Capital LLC (Trc) transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 20,311 shares of RPHM stock, worth $34,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,311
Previous 14,939 35.96%
Holding current value
$34,122
Previous $22,000 54.55%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.34 - $1.7 $7,198 - $9,132
5,372 Added 35.96%
20,311 $34,000
Q2 2024

Aug 13, 2024

BUY
$1.51 - $1.9 $8,246 - $10,375
5,461 Added 57.62%
14,939 $22,000
Q1 2024

May 15, 2024

BUY
$1.59 - $1.74 $4,297 - $4,703
2,703 Added 39.9%
9,478 $15,000
Q4 2023

Feb 13, 2024

BUY
$1.34 - $8.43 $7,097 - $44,653
5,297 Added 358.39%
6,775 $10,000
Q3 2023

Nov 14, 2023

BUY
$5.44 - $8.13 $4,020 - $6,008
739 Added 100.0%
1,478 $11,000
Q2 2023

Aug 14, 2023

SELL
$5.44 - $10.5 $9,449 - $18,238
-1,737 Reduced 70.15%
739 $4,000
Q1 2023

May 09, 2023

SELL
$2.44 - $6.42 $8,398 - $22,097
-3,442 Reduced 58.16%
2,476 $15,000
Q4 2022

Feb 10, 2023

BUY
$1.8 - $3.52 $10,652 - $20,831
5,918 New
5,918 $14,000
Q2 2022

Aug 15, 2022

SELL
$1.96 - $3.04 $16,681 - $25,873
-8,511 Reduced 86.85%
1,289 $3,000
Q1 2022

May 12, 2022

BUY
$2.94 - $9.07 $25,169 - $77,648
8,561 Added 690.96%
9,800 $29,000
Q4 2021

Feb 14, 2022

SELL
$6.07 - $9.68 $339 - $542
-56 Reduced 4.32%
1,239 $11,000
Q3 2021

Nov 15, 2021

BUY
$6.28 - $11.07 $7,856 - $13,848
1,251 Added 2843.18%
1,295 $10,000
Q2 2021

Aug 16, 2021

BUY
$7.78 - $15.0 $342 - $660
44 New
44 $0

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.